InMed Pharmaceuticals Inc.
INM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 3 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $4.18M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding InMed Pharmaceuticals Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 19 | 18 | −1 |
| Shares | 363.1K | 1.10M | +733.7K (+202.1%) |
| Value | $341.9K | $514.5K | +$172.6K (+50.5%) |
New holders (3)
Institutions that held InMed Pharmaceuticals Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 956,118 | $450.0K | 0.01% |
| Citadel Advisors LLC | 12,966 | $6.00K | 0.00% |
| Morgan Stanley | 17 | $0 | 0.00% |
Sold out (4)
Institutions that held InMed Pharmaceuticals Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Empery Asset Management, LP | 61,741 | $58.0K |
| Two Sigma Investments, LP | 39,700 | $37.0K |
| Two Sigma Securities, LLC | 17,979 | $17.0K |
| Millennium Management LLC | 14,069 | $13.0K |